ArticleJAAD case reports2017
Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases.
Article in JAAD case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment.Oncology research · 2025Review
- A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma.Clinical case reports · 2024Article
- Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.Current oncology reports · 2024Review
- The Evolving Treatment Landscape of Merkel Cell Carcinoma.Current treatment options in oncology · 2023Review
- Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec.JAAD case reports · 2023Article
- Review
- Talimogene Laherparepvec in Non-Melanoma Cancers.The Journal of clinical and aesthetic dermatology · 2021Review
- Current concepts and approaches to merkel cell carcinoma.Archives of dermatological research · 2021Review
- How we treat Merkel cell carcinoma: within and beyond current guidelines.Future oncology (London, England) · 2021Article
- Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.Cancer immunology, immunotherapy : CII · 2020Article
- Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8Cancer immunology research · 2020Article
- Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.Frontiers in oncology · 2020Article
- Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma.JAAD case reports · 2019Article
- Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.The oncologist · 2019Review
- Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients.JAAD case reports · 2019Article
- Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma.JAAD case reports · 2018Article
- Immunotherapy for Merkel Cell Carcinoma.Current treatment options in oncology · 2018Review
- Talimogene laherparepvec: First in class oncolytic virotherapy.Human vaccines & immunotherapeutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.